HLA-DR9 antigen

Also Known As:

HLA DR9; HLA DRw9; HLA-DR9; HLA-DRw9; HLA-DRw9 antigen

Networked: 37 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Glycoproteins: 24834
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37
  - Membrane Proteins: 10078
    - Membrane Glycoproteins: 2252
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37
Biological Factors: 2472
- Antigens: 143924
  - Surface Antigens: 5813
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37
  - Isoantigens: 1221
    - Histocompatibility Antigens: 1132
      - HLA Antigens: 8934
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37
      - Histocompatibility Antigens Class II: 2170
        HLA-D Antigens: 238
        HLA-DR Antigens: 5477
        HLA-DR Serological Subtypes
        HLA-DR9 antigen: 37

Experts

1.	Kanazawa, Yasuhiko: 2 articles (10/2006 - 12/2004)
2.	Maruyama, Taro: 2 articles (10/2006 - 12/2004)
3.	Motohashi, Yoshiko: 2 articles (10/2006 - 12/2004)
4.	Oikawa, Yoichi: 2 articles (10/2006 - 12/2004)
5.	Okubo, Yoshiaki: 2 articles (10/2006 - 12/2004)
6.	Shigihara, Toshikatsu: 2 articles (10/2006 - 12/2004)
7.	Shimada, Akira: 2 articles (10/2006 - 12/2004)
8.	Celis, Esteban: 2 articles (05/2005 - 10/2004)
9.	Kimura, Shoji: 2 articles (05/2005 - 10/2004)
10.	Kobayashi, Hiroya: 2 articles (05/2005 - 10/2004)

Related Diseases

1.	Myasthenia Gravis 08/01/1987 - "Association of HLA-DRw9 with myasthenia gravis in Chinese." 03/01/1989 - "Generalized myasthenia gravis occurs predominantly in patients presenting after the age of 20 years and is accompanied by high titres of acetylcholine receptor antibody but is less strongly associated with HLA-DRw9. " 05/01/1988 - "The relationship between the histocompatibility leukocyte antigen (HLA) phenotypes and the clinical course of myasthenia gravis (MG) was studied in 53 Japanese patients with MG. The frequency of HLA-DRw9 antigen was high in the MG patients who did not need immunosuppressive therapy but only anticholinesterase agents (RR = 4.52; CP less than 0.02), who achieved remission of the disease (RR = 2.98; CP less than 0.05) or who showed a decrease in AChR antibody (Ab) titer (RR = 6.32; CP less than 0.0002), whereas the frequency of HLA-DRw8 antigen was increased in MG patients who underwent immunosuppressive therapy (RR = 4.03; CP less than 0.01), who did not have remission (RR = 4.75; CP less than 0.1) or who showed an increase in AChR Ab titer (RR = 6.48; CP less than 0.01). "
2.	Disease Progression 03/01/1992 - "Patients with HLA-DR9 and DRw8 showed the highest ratio of patients who had protracted clinical course; those with HLA-DR2, DR5 and DR6 showed the lowest; and those with HLA-DR4, DRw52 and Drw53 were between these levels. " 05/01/1988 - "The relationship between the histocompatibility leukocyte antigen (HLA) phenotypes and the clinical course of myasthenia gravis (MG) was studied in 53 Japanese patients with MG. The frequency of HLA-DRw9 antigen was high in the MG patients who did not need immunosuppressive therapy but only anticholinesterase agents (RR = 4.52; CP less than 0.02), who achieved remission of the disease (RR = 2.98; CP less than 0.05) or who showed a decrease in AChR antibody (Ab) titer (RR = 6.32; CP less than 0.0002), whereas the frequency of HLA-DRw8 antigen was increased in MG patients who underwent immunosuppressive therapy (RR = 4.03; CP less than 0.01), who did not have remission (RR = 4.75; CP less than 0.1) or who showed an increase in AChR Ab titer (RR = 6.48; CP less than 0.01). "
3.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 10/01/2006 - "Moreover, we found a significant correlation between autoimmune-related type 1 diabetes with HLA DR9 and detection of GAD-reactive Th1 (T helper 1)-type cells. " 12/01/2004 - "There was an association between T cell reactivity against GAD and HLA DR9 in Japanese type 1 diabetes." 11/01/1992 - "The HLA-DR9 haplotype, which is associated positively with IDDM in Japanese, was associated with DQA10301 and DQB10303, indicating that the Japanese DR9 haplotype is the same as that in caucasians but different from that in blacks. " 05/01/1992 - "Previous studies have shown that insulin-dependent diabetes mellitus is positively associated with HLA-DR4 and HLA-DR9 in Japanese populations. " 10/01/2006 - "Frequency of CTLA-4 gene CT60 polymorphism may not be affected by vitamin D receptor gene Bsm I polymorphism or HLA DR9 in autoimmune-related type 1 diabetes in the Japanese."
4.	Seasonal Allergic Rhinitis (Hay Fever) 11/01/1997 - "We have previously reported a positive association between the HLA-DR9 phenotype and the development of birch pollen allergy in Japanese subjects. " 01/01/1997 - "Previously, we have reported the positive association of birch pollen allergy in HLA-DR9 antigen. " 04/01/1992 - "The results of the HLA population study indicated that HLA-DR9 and HLA-DQw3 correlated with the development of birth pollinosis (relative risk [R. " 09/01/1994 - "We have previously reported the positive association of the pollinosis with HLA-DR9 antigens. "
5.	Infections 09/01/2009 - "In our study, we found that the HLA-DR9 allele and HPV16E6 infection had a function of synergy in the process of malignant transformation of esophageal epithelial cells, and jointly promoting the occurrence and development of EC." 09/01/2009 - "In the controls, the rates of HPV16E6 infection were 22.2% and 16.2% among individuals with HLA-DR9 allele atatus as positive or negative, and without statistically significant difference. " 09/01/2009 - "The rate of HPV16E6 infection in individuals with HLA-DR9 allele was different from the ones who were HLA-DR9 allele free (chi(2) = 7.57, P = 0.006), with OR value as 5.79 (95%CI: 1.53 - 21.87). " 09/01/2009 - "HPV16E6 infection and HLA-DR9 allele positive status were the risk factors for EC, with OR values as 2.67 (95%CI: 1.38 - 5.17) and 3.83 (95%CI: 1.48 - 9.96) respectively. " 05/01/2003 - "HLA-DR9 and DQ9 are associated with chronicity of HBV infection."

Related Drugs and Biologics

1.	Antigens
2.	HLA-DR8 antigen
3.	Cholinesterase Inhibitors (Anticholinesterases)
4.	HLA-DR4 Antigen (HLA DR4 Antigen)
5.	HLA-DQ3 antigen
6.	Peptides (Polypeptides)
7.	HLA-DR3 Antigen (HLA DR3 Antigen)
8.	Antibodies
9.	HLA-B46 antigen
10.	Calcitriol Receptors (Calcitriol Receptor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)